The prevalence of anti-NuMA1 and anti-NuMA2 antibodies in autoimmune, hepatic, infectious and renal inflammatory diseases is well known; however, its presence and possible relevance in cardiovascular diseases still needs to be elucidated. Aim: To evaluate the prevalence of positive anti-NuMA1 and anti-NuMA2 antibody patterns in subjects with autoimmune, non-autoimmune and/or cardiac diseases. Material and methods: This was an observational study run from January 2010 to January 2018. Individuals whose treating physician requested an antibody study and we detected anti NuMA1 and anti NuMA2 pattern in any patients. The files from these patients were reviewed to obtain general data, signs, symptoms, time of evolution of the disease, determination of specific antibodies and the established diagnoses. Results: From a total of 7163 patient files 46 had NuMA1 pattern and out of them 24 (52%) had autoimmune disease (AD): 8 rheumatoid arthritis, 10 systemic lupus erythematosus (SLE), 2 antiphospholipid syndrome, 1 polymyositis, 1 fibromyalgia, 1 primary Sjogren and 1 Devic syndrome. In 15 patients (32%), cardiovascular diseases (CVD) were diagnosed and in only one of them there was an associated autoimmune disease. In three patients, there was a positive specificity for anti-SSA antigen, RNP in addition to the anti-NuMA. Rheumatoid factor, anti B2glicoprotein was present in 1 patient. Anti NuMA1 was found in 4 patients (9%); one of which had kidney disease and 3 had cardiopulmonary disease (7%). Eleven patients were positive to anti-NuMA2, five with autoimmune diseases (46%), one with cardiovascular disease (9%), two with cardiopulmonary diseases (18%) and three with renal disease (27%). Conclusion: The prevalence of high levels of antinuclear antibodies with a NuMA1 and/or NuMA2 pattern is present in patients having cardiovascular disease without there being a coexisting autoimmune disease. This finding may indicate a specific form of autoimmunity.

The proteins of the nuclear mitotic apparatus (NuMA), which weigh238 kDa, are located in the nucleus during interphase and accumulateat the spindle poles during mitosis. They belong to the BimCkinesin protein family which is distributed in the spindle duringcellular division. They are found in the spindle poles duringmetaphase and anaphase participating in the microtubule movement and stabilization of the mitotic spindle.

These proteins have specific functions during mitosis (spindlestabilization, centromere maturation, cytokinesis, and post-mitoticnuclear rearrangement). Five different types of antigens in the NuMAhave been described: NuMA1 and NuMA2, centrosome (CE), middlebody (MB) and F-centromere (CENP-F).

Journal of Clinical Pharmacology and Toxicology is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal of Clinical Pharmacology and Toxicology or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

On the occasion of its 3 years, Successful Journey, Journal of Clinical Pharmacology and Toxicology decided to provide a partial waiver on its article processing charges to promote quality research from across the nations of the globe to encourage the latest research in the field of Infections, Diseases and Medicine. Journal of Clinical Pharmacology and Toxicology also planning to release a special issue on its new approaches.

Regards

Mary Wilson

Editorial office

Journal of Clinical Pharmacology and Toxicology

E-mail: pharmatoxicol@eclinicalsci.com

Tel & Whats app:  +1-947-333-4405